Cures Within Reach Announces Repurposing Research Projects Funded In Fourth Quarter 2016
SKOKIE, Ill. - Dec. 5, 2016 - PRLog -- Cures Within Reach announced an addition to their portfolio of repurposing research projects, selected for funding, beginning in the fourth quarter of 2016. Seven projects will receive a total of $291,880 in support. Conditions covered by these research projects include two rare diseases, plus macular degeneration, pancreatic cancer, depression and post-traumatic stress disorder (PTSD). All projects were submitted and vetted via CureAcceleratorTM, the online repurposing platform created by Cures Within Reach.
"We're pleased to add these new projects to our current research portfolio," said Dr. Clare Thibodeaux, Director of Scientific Affairs for Cures Within Reach. "We believe this repurposing research has the ability to improve patient outcomes, and we look forward to seeing the results as they develop. We also appreciate the feedback and support we received from our grant reviewers and our Science Advisory Board in selecting the final projects."
The two rare conditions in this funding cycle are myotubular myopathy, a neuromuscular disease, and hypercalcemia and hypercalciuria caused by a genetic defect affecting vitamin D metabolism. Support for this research comes from a collaboration between the Canadian Institutes of Health Research (CIHR) and Cures Within Reach to fund proof of concept repurposing clinical trials in rare diseases. Research will be conducted at sites in both the United States and Canada.
"Working with the Canadian Institutes of Health Research has allowed Cures Within Reach to promote cross-border collaboration within the research community," stated Dr. Bruce Bloom, President and Chief Science Officer for Cures Within Reach. "We are committed to increasing the global impact of repurposing for patients and scientists alike, and our partnership with CIHR has helped us advance our mission."
The remaining projects are funded through a grant from a private foundation wishing to support repurposing research in the Mid-Atlantic region, plus a grant from the Young Minds Foundation, focused on creating treatments for depression and PTSD. Research will be conducted at the University of Pennsylvania in Philadelphia, PA, Johns Hopkins University in Baltimore, MD and Virginia Tech in Blacksburg, VA.
ABOUT CURES WITHIN REACH
Cures Within Reach (http://www.cureswithinreach.org) works to catalyze repurposing research to quickly and affordably improve patient lives. We accomplish this through collaborations that connect researchers and funding, by facilitating crowd sourcing and community, and by identifying alternative financing models and incentives. Cures Within Reach's repurposing research projects have generated 12 "new" treatments making an impact through off-label use in clinical practice or through a commercialization track. Cures Within Reach currently has 24 repurposing research projects either funded or approved for funding.
ABOUT CUREACCELERATOR™
Cures Within Reach built CureAccelerator (http://www.cureaccelerator.org) to provide a global collaboration space and market for repurposing research that can deliver effective solutions to unsolved diseases. The CureAccelerator platform was built with a grant from the Robert Wood Johnson Foundation, to explore whether drugs, devices and nutriceuticals approved for one or more human diseases can be repurposed to create "new" treatments in other diseases. CureAccelerator has over 1000 users who have proposed 120 projects, of which more than 20 have received funding and are moving towards patient impact.
Visit us at www.cureswithinreach.org or follow us via Twitter.com/
"We're pleased to add these new projects to our current research portfolio," said Dr. Clare Thibodeaux, Director of Scientific Affairs for Cures Within Reach. "We believe this repurposing research has the ability to improve patient outcomes, and we look forward to seeing the results as they develop. We also appreciate the feedback and support we received from our grant reviewers and our Science Advisory Board in selecting the final projects."
The two rare conditions in this funding cycle are myotubular myopathy, a neuromuscular disease, and hypercalcemia and hypercalciuria caused by a genetic defect affecting vitamin D metabolism. Support for this research comes from a collaboration between the Canadian Institutes of Health Research (CIHR) and Cures Within Reach to fund proof of concept repurposing clinical trials in rare diseases. Research will be conducted at sites in both the United States and Canada.
"Working with the Canadian Institutes of Health Research has allowed Cures Within Reach to promote cross-border collaboration within the research community," stated Dr. Bruce Bloom, President and Chief Science Officer for Cures Within Reach. "We are committed to increasing the global impact of repurposing for patients and scientists alike, and our partnership with CIHR has helped us advance our mission."
The remaining projects are funded through a grant from a private foundation wishing to support repurposing research in the Mid-Atlantic region, plus a grant from the Young Minds Foundation, focused on creating treatments for depression and PTSD. Research will be conducted at the University of Pennsylvania in Philadelphia, PA, Johns Hopkins University in Baltimore, MD and Virginia Tech in Blacksburg, VA.
ABOUT CURES WITHIN REACH
Cures Within Reach (http://www.cureswithinreach.org) works to catalyze repurposing research to quickly and affordably improve patient lives. We accomplish this through collaborations that connect researchers and funding, by facilitating crowd sourcing and community, and by identifying alternative financing models and incentives. Cures Within Reach's repurposing research projects have generated 12 "new" treatments making an impact through off-label use in clinical practice or through a commercialization track. Cures Within Reach currently has 24 repurposing research projects either funded or approved for funding.
ABOUT CUREACCELERATOR™
Cures Within Reach built CureAccelerator (http://www.cureaccelerator.org) to provide a global collaboration space and market for repurposing research that can deliver effective solutions to unsolved diseases. The CureAccelerator platform was built with a grant from the Robert Wood Johnson Foundation, to explore whether drugs, devices and nutriceuticals approved for one or more human diseases can be repurposed to create "new" treatments in other diseases. CureAccelerator has over 1000 users who have proposed 120 projects, of which more than 20 have received funding and are moving towards patient impact.
Visit us at www.cureswithinreach.org or follow us via Twitter.com/
End
| Tags | : | Drug Repurposing, Research, Rare Diseases |
|---|---|---|
| Industry | : | Non-profit |
| Location | : | Skokie - Illinois - United States |